Senate Bill Would Narrow Rare Disease Drug Monopolies to Specific Approved Uses
Smaller biotech and pharmaceutical companies that develop treatments for rare diseases would have an easier path to market. Under current rules, a single company's broad exclusivity over an entire rare disease can block competitors even if they're targeting a different use or mechanism. This change opens the door for smaller firms to pursue niche treatments within the same disease space without waiting out a full 7-year exclusivity period.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
No votes have been recorded for this legislation yet.
The legislation revises how Orphan Drug exclusivity is applied, changing the standard from the 'same disease or condition' to the 'same approved use or indication.' This allows generic competitors to market drugs for new uses or patient populations sooner.
During a House hearing, medical experts urged Congress to advance the Retaining Access and Restoring Exclusivity (RARE) Act, which would limit orphan drug exclusivity to the approved indication to encourage market competition and lower costs for rare disease treatments.
The Consolidated Appropriations Act, 2026, codifies the FDA's longstanding interpretation of the Orphan Drug Act by limiting the scope of seven-year exclusivity to the indication ultimately approved, effectively reversing the controversial Catalyst v. Becerra court decision.
Document Type
Congressional Bill
Official Title
RARE Act
Analysis generated by AI. Always verify with official sources.